In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
News|Articles|August 19, 2026
Trump Expected to Tap Heidi Overton as FDA Commissioner
Author(s)Stephen Appezzato
Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust.
Advertisement
Advertisement
President Donald Trump is expected to pick Heidi Overton, a physician and White House domestic policy aide, to lead the FDA, according to a source familiar with the matter.1 If confirmed by the Senate, Overton would succeed Marty Makary, who
Related to this article
HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Advertisement
Advertisement